News sentiment analysis powered by sentiment-insight.com
One Blue Label Telecoms Insider Raised Their Stake In The Previous Year
Blue Label Telecoms Limited's (JSE:BLU) insider transactions over the last year. The biggest single purchase by an insider was when Co-Founder Mark Levy bought R3.8m worth of shares at a price of R2.85 per share. We like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed.
Blue Label Telecoms Full Year 2023 Earnings: EPS: R0.30 (vs R1.17 in FY 2022) Blue Label Telecoms (JSE:BLU) Full Year 2023 Results. Revenue: R18.7b (up 7.4% from FY 2022).Net income: R269.0m (down 74% fromfy 2022).Profit margin: 1.4%.EPS: R0.30 (down from R1.17 in FY 2022) Shares down 16% from a week ago.
Risks To Shareholder Returns Are Elevated At These Prices For GRP Limited (SGX:BLU) GRP Limited (SGX:BLU) has a median price-to-sales ratio of 0.8x. The company has been growing its revenue at a really rapid pace. The P/S is probably moderate because investors think this strong revenue growth might not be enough to outperform the broader industry in the near future. There's a good chance existing shareholders are setting themselves up for future disappointment.
Should You Be Impressed By Blue Label Telecoms Limited's (JSE:BLU) ROE? Blue Label Telecoms Limited (JSE:BLU) has a ROE of 11%, based on a net profit of R433m. The figure is based on the net profit divided by the number of shareholders' equity. We like to see a high ROE, but it doesn't necessarily mean the business is good. One way to determine if a company has a good ROE is to compare it to the average in its industry.
Bellus: Q1 Earnings Snapshot Bellus Health Inc. (BLU) on Friday reported a loss of $25.1 million in its first quarter. The drug developer posted revenue of $3,000 in the period. Bellus shares have climbed 76% since the beginning of the year.
Bellus: Q1 Earnings Snapshot Bellus Health Inc. (BLU) on Friday reported a loss of $25.1 million in its first quarter. The drug developer posted revenue of $3,000 in the period. Bellus shares have climbed 76% since the beginning of the year.
Bellus: Q1 Earnings Snapshot Bellus Health Inc. (BLU) reported a loss of $25.1 million in its first quarter. The drug developer posted revenue of $3,000 in the period. Bellus shares have climbed 76% since the beginning of the year.
Blue Label Telecoms Limited's (JSE:BLU) Business And Shares Still Trailing The Market Blue Label Telecoms Limited (JSE:BLU) has a 4.1x P/E ratio. The company grew earnings per share by an impressive 28% last year. However, the latest three year period hasn't been as great in aggregate as it didn't manage to provide any growth at all.
Blue Label Telecoms Limited (JSE:BLU) insiders have significant skin in the game with 34% ownership Blue Label Telecoms Limited (JSE:BLU) has a 34% stake in the company. The largest shareholder, Allan Gray Limited, has a 14% stake. The second largest shareholder holds about 14% of the shares.
Sign Up
